Komen breast cancer charity cancels walks in seven U.S. cities

DALLAS Tue Jun 4, 2013 10:37pm EDT

A sign for the Susan G. Komen Foundation's 2012 Race for the Cure is displayed in Washington June 2, 2012. REUTERS/Joshua Roberts

A sign for the Susan G. Komen Foundation's 2012 Race for the Cure is displayed in Washington June 2, 2012.

Credit: Reuters/Joshua Roberts

Related Topics

Photo

Ebola epidemic

Quarantines and isolation units imposed to stop the spread of the worst Ebola outbreak in history.  Slideshow 

DALLAS (Reuters) - Breast cancer charity Susan G. Komen for the Cure, which suffered a publicity backlash last year after it sought to cut funding to Planned Parenthood, said on Tuesday it was canceling fundraising walks next year in seven cities where money goals have not been met.

The organization, which says it is the largest non-government funder of breast cancer research, said it was cutting three-day walks for 2014 in Phoenix, Boston, Chicago, Cleveland, Tampa Bay, San Francisco and Washington. The event will continue in seven other places.

"The difficult decision to exit these markets was not made lightly, as we know this bold and empowering event has touched the lives of thousands of participants like you," the Dallas-based group said in a message on its Facebook page.

A Komen spokeswoman said in an email that participation in the three-day walks declined by 37 percent in the past four years, without specifying whether that was the number of participants or dollars raised. The group decided to remove the cities from next year's schedule that have not been meeting fundraising goals, the spokeswoman said.

It was unclear what the group's fundraising targets were for the walks. Each participant is required to raise a minimum of $2,300 and walks about 60 miles over the three days.

The charity sparked an outcry last year when it said it would cut funding to Planned Parenthood, a provider of birth control, abortion and other women's health services.

Komen, which supports Planned Parenthood's efforts to provide access to breast-cancer screening, reversed that decision within days and said it would restore the funding.

After the controversy, several of the group's leaders stepped down, and the group's founder, Nancy Brinker, stepped down as CEO, though she continued to hold a management role.

Brinker founded the organization in 1982, two years after her sister, Susan G. Komen, died of breast cancer.

Komen's signature event is the Race for the Cure, which includes 5 kilometers and marathon races as well as the walks. The group says the events involve more than 1.7 million participants each year.

Komen will continue to hold walks in Atlanta, Dallas/Fort Worth, Michigan, Philadelphia, San Diego, Seattle and Minneapolis-St. Paul.

(Editing by Edith Honan and Cynthia Osterman)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (13)
cimach wrote:
Or maybe most of us just don’t support the killing of unborn children anymore.

Jun 04, 2013 9:17pm EDT  --  Report as abuse
r.u.crazy wrote:
They should have stuck to their original model of breast cancer research. They should have stayed out of the planned parenthood argument. I don’t believe anyone was offended by the breast cancer research but like many charitable organizations, their popularity is waning. Charitable organizations have no business paying their executives in the high six figures. United Way comes to mind also. Greed always finds a way.

Jun 04, 2013 9:29pm EDT  --  Report as abuse
avatar2001 wrote:
Life begins at conception and ends at birth

Jun 04, 2013 9:36pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.